Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma S Jones

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical Science (London, England : 1979)|July 18, 2015
β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive ratsMark Del Borgo, Yan Wang, Sanja Bosnyak, et al.
Clinical Science (London, England : 1979)|March 24, 2020
Renal functional effects of the highly selective AT2R agonist, β-Pro7 Ang III, in normotensive ratsLucinda M Hilliard Krause, Brandon A Kemp, Amanda Suan Jui Tan, et al.
Allergy|September 30, 2022
Clinical and laboratory features of patients diagnosed with alpha-gal syndrome-2010-2019Alison M Binder, Dena Cherry-Brown, Brad J Biggerstaff, et al.
Kidney International|January 17, 2014
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosisBryna S Man Chow, Martina Kocan, Sanja Bosnyak, et al.
Hypertension (Dallas, Tex. : 1979)|February 9, 2011
A single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular functionEmma S Jones, Mark P Del Borgo, Julian F Kirsch, et al.
ACS Chemical Biology|May 3, 2014
Electronic sculpting of ligand-GPCR subtype selectivity: the case of angiotensin IIFrancesca Magnani, Charalampos G Pappas, Tim Crook, et al.
Hypertension (Dallas, Tex. : 1979)|October 4, 2012
Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated miceChristopher T Chan, Jeffrey P Moore, Klaudia Budzyn, et al.
MMWR. Morbidity and Mortality Weekly Report|July 2, 2026
Alpha-gal Immunoglobulin E Seroprevalence Among Blood Donors - 10 States, 2024-2025Eleanor F Saunders, Marissa L Taylor, Emma S Jones, et al.
The Journal of Infectious Diseases|May 5, 2022
Predominance of Severe Plasma Leakage in Pediatric Patients With Severe Dengue in Puerto RicoGabriela Paz-Bailey, Liliana Sánchez-González, Brenda Torres-Velasquez, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 10, 2024
Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020Marissa L Taylor, Gilbert J Kersh, Johanna S Salzer, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Science (London, England : 1979)|July 18, 2015
β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive ratsMark Del Borgo, Yan Wang, Sanja Bosnyak, et al.
Clinical Science (London, England : 1979)|March 24, 2020
Renal functional effects of the highly selective AT2R agonist, β-Pro7 Ang III, in normotensive ratsLucinda M Hilliard Krause, Brandon A Kemp, Amanda Suan Jui Tan, et al.
Allergy|September 30, 2022
Clinical and laboratory features of patients diagnosed with alpha-gal syndrome-2010-2019Alison M Binder, Dena Cherry-Brown, Brad J Biggerstaff, et al.
Kidney International|January 17, 2014
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosisBryna S Man Chow, Martina Kocan, Sanja Bosnyak, et al.
Hypertension (Dallas, Tex. : 1979)|February 9, 2011
A single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular functionEmma S Jones, Mark P Del Borgo, Julian F Kirsch, et al.
ACS Chemical Biology|May 3, 2014
Electronic sculpting of ligand-GPCR subtype selectivity: the case of angiotensin IIFrancesca Magnani, Charalampos G Pappas, Tim Crook, et al.
Hypertension (Dallas, Tex. : 1979)|October 4, 2012
Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated miceChristopher T Chan, Jeffrey P Moore, Klaudia Budzyn, et al.
MMWR. Morbidity and Mortality Weekly Report|July 2, 2026
Alpha-gal Immunoglobulin E Seroprevalence Among Blood Donors - 10 States, 2024-2025Eleanor F Saunders, Marissa L Taylor, Emma S Jones, et al.
The Journal of Infectious Diseases|May 5, 2022
Predominance of Severe Plasma Leakage in Pediatric Patients With Severe Dengue in Puerto RicoGabriela Paz-Bailey, Liliana Sánchez-González, Brenda Torres-Velasquez, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 10, 2024
Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020Marissa L Taylor, Gilbert J Kersh, Johanna S Salzer, et al.
Pageof 4